Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

About
About
Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Explore section
Our Strategy and Values

People
Lead Products
Lead Products
Through development and commercialisation of lead assets such as Accrufer^® / Feraccru^® and PT20, Shield continues to build an integrated and ultimately profitable speciality pharmaceutical business.
Explore section
Accrufer^® / Feraccru^®
Pipeline product candidate

Publications
Partnering
Investors
Investors
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
Overview

RNS News

Share Price Summary

Corporate Governance

AIM Rule 26

Video and Audio

Investor Contacts

Corporate Documents

Presentations

Advisor Contacts

Financial Calendar

Analyst Coverage
News
Events
Careers

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement.

19 Sep 2018

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand.

For further details see the attachment below.

STX_Exclusive Licence Agreement

Back to news

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement.

Sign up for news